Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia - Test2 - elhamkhani - TriplyDB

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

http://www.wikidata.org/entity/Q28240120

about

Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice.Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options A review of anti-inflammatory agents for symptoms of schizophrenia In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis.Neurosteroids: endogenous role in the human brain and therapeutic potentials Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials Treating Negative Symptoms in Schizophrenia: an Update Improvement of Psychotic Symptoms and the Role of Tissue Plasminogen Activator GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the AKT/GSK3β pathway.Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults.Expression of GABAA α2-, β1- and ε-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder Progesterone reduces hyperactivity of female and male dopamine transporter knockout mice Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression.GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders.Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.Differential effects of ethanol on serum GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in mice, rats, cynomolgus monkeys, and humans.Neuropathic pain promotes adaptive changes in gene expression in brain networks involved in stress and depression A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Peripheral oxytocin is associated with reduced symptom severity in schizophrenia Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits.Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder Pregnenolone and ganaxolone reduce operant ethanol self-administration in alcohol-preferring p rats.A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment.From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.Schizophrenia: a systemic disorder The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons Pregnenolone sulfate as a modulator of synaptic plasticity.Neuropsychological profile in adult schizophrenia measured with the CMINDS The neurosteroids allopregnanolone and dehydroepiandrosterone modulate resting-state amygdala connectivity.Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research.Neurosteroids, stress and depression: potential therapeutic opportunities.The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional N-methyl D-aspartate receptors to the cell surface via a noncanonical, G protein, and Ca2+-dependent mechanism.

P2860

Q21133801-1B9BB8D7-E2BF-497E-8B37-F2D0344ABEC3 Q22241447-3A7CBB32-D561-46CF-BE5A-7AA5738FB131 Q22241827-E32D8062-9685-4887-A5B3-039B2AE85FF9 Q24605563-BDF07607-26DF-437B-BEC3-3602D94A5FC6 Q24632113-C5BB294E-6705-4947-849E-4FB387D95181 Q26741541-79AE8F3F-9872-4C3C-913D-FA611060781E Q26744805-CE1110CD-0097-46F7-8FD4-1AEF96024376 Q26828527-3DB45311-825D-45E3-B12D-4944223D9467 Q30363617-CC467402-74D6-4327-BBFB-16DEBC6AD025 Q30371274-7F7800BE-264A-4E27-B725-C852822D6EF4 Q30416840-D90DADE2-4311-4D70-AC32-78CD711C043A Q30439296-D4E824A4-065E-4F89-9383-BDED176161CA Q30448885-2F1B3E33-D4AB-4262-8CEE-DC97A44D5010 Q30455767-8C8BA25D-248F-4809-9CB2-6C339D74BFF5 Q30467322-055BFDD8-30AC-4FA5-8D94-1F59231F1187 Q30479407-5D8EA75C-FFA0-44A3-98B9-11D03F46B590 Q30536299-871752E0-838F-4104-9080-DC83AB0B4512 Q33703907-3163762E-A5F4-4522-86C6-B85CCD1DDA24 Q33805010-A71B4CAE-9633-47E3-B2D4-DA54070F463B Q33925526-391CAEB2-D7B8-463D-939F-9EC1FCE279CD Q34186056-6EF25A02-E5CF-4506-963E-505A0AD1A5A8 Q34274859-4A5239AE-6F0E-4567-A05E-BAEE4BDC6057 Q34311629-B79A71F6-9954-49A5-91EC-812F5FA5B140 Q34324221-D4F89FDD-317D-416B-922A-FE60CA326D7C Q34325264-362240D4-8043-4A45-B5E8-40297445BAFB Q34336607-F5D1296C-F57B-4E0A-B6A4-C9F6AA80F343 Q34357016-78CE4E40-05DC-476A-8E1E-3FA8A910F093 Q34401854-AB235176-8019-40F7-BC2E-527C56182679 Q34556039-437A0874-A961-4422-87A0-C7E7066D6FEC Q34632695-7D1669C3-533D-4406-8ADB-3EF30C9A88B1 Q35323907-8EADAF13-8025-4D63-A751-58C28C3BA714 Q35390239-B40C5AB3-8FAE-4A68-8E97-DD173A435ED3 Q35631836-47906CD9-FCE4-44CB-BC16-535200773794 Q35988739-961171AB-3600-4A60-A4D5-CFC0DC69AC92 Q36224315-59C78B24-F0BE-4014-800E-1F3E4140AAC7 Q36408176-2FD28ACC-27B4-4889-8DAD-60ED9EE1E9BA Q36538076-F919EDA4-66ED-4813-BBA2-4A971A02B659 Q36626032-4932FD88-613B-4934-B545-B34CB2640CAC Q36666746-A7DF6446-9118-48B1-BE15-BEF1B539C2DA Q37027057-99E7097D-C43B-4647-8612-F03EA9D87CF7

P2860

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

http://www.wikidata.org/entity/Q28240120

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@ast

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@en

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@nl

type

label

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@ast

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@en

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@nl

prefLabel

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@ast

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@en

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@nl

P1433

Q28240120-749495EF-2E22-4AB2-95BB-FCD9A3F10A7F

P1476

Q28240120-9404B16F-1C92-4EF1-BBE9-813176F59192

P2093

Q28240120-0F1BD205-E0DC-43F5-BEB8-757CBBF137E2

Q28240120-1AC9B6F2-5F6F-4044-BA04-2B8BB055E5C8

Q28240120-1BBE5F2E-55C5-4779-9EDE-618AF3B631DC

Q28240120-2564D038-0293-4303-B18A-94C8B1F2E8CA

Q28240120-6A70687F-BFFD-41B2-B8ED-81421BBAE6FB

Q28240120-81B26EAB-CDFF-48B7-BF57-0DA0EDA9739C

Q28240120-8FEB4074-AE6E-4CEE-AA88-634A06882017

Q28240120-994C08D8-A414-4D21-8CC8-BA4DCB05F589

Q28240120-9D74F971-0D28-4239-B725-850031A21DAF

Q28240120-A18B00CB-F8CA-486D-84A6-88E547532B16

P2860

Q28240120-03C48A95-A031-4249-87B9-881649D2E486

Q28240120-040BBFEB-1F1A-4D75-89C0-77835BA8F837

Q28240120-06D66C3E-40AE-490C-929F-6530D66C9ACF

Q28240120-07E28C7F-8D1E-4266-B35D-1D96DE87120F

Q28240120-09384A37-3258-4105-81BA-1D099F0ADB04

Q28240120-12060CBD-E50B-4701-91CA-A3650249C7C4

Q28240120-1430DC0C-37C1-44FC-A840-2763B717967B

Q28240120-14620BA8-6DAA-42B6-87F4-2826581FC8A3

Q28240120-1765CFE4-F20D-47C3-9F34-0F9BFD9FDA35

Q28240120-1CA902A8-1FEE-42E3-BACC-C54EB7D58A39

P2888

Q28240120-345CD257-BF00-4AD5-89F4-C1CB79950956

P304

Q28240120-2C485867-65F8-4656-AAC4-7F3A54A6C4A5

P31

Q28240120-D66DDF98-C6A7-417C-8C34-4277F690D22F

P3181

Q28240120-F0535E95-9DBF-4B83-98BF-0423886D81AC

P356

Q28240120-8A8F1884-2232-4D68-A810-19E072576E30

P407

Q28240120-56F9A21F-ED19-4390-BF2C-7A90EF2A3150

P433

Q28240120-402C6659-C276-4E75-92BA-766F4EB0B94D

P478

Q28240120-8687C312-AD28-4E69-A4A3-288F88089740

P50

Q28240120-41498EFC-4A91-4AA1-AEE1-AAE6D6D67E53

P577

Q28240120-794CB959-C72D-4C76-821F-3EE1C6FB40BB

P5875

Q28240120-240EED55-79FE-4D8C-BF3F-51F780A9BB72

P6179

Q28240120-E8956865-D90F-43DB-92D6-13B063C45A4D

P698

Q28240120-CD3814C5-7D76-4A21-BEC7-D5FCB194FB70

P921

Q28240120-B7E50360-209A-4F72-8A54-5A4EB3650000

P932

Q28240120-F8B5F601-F918-4899-B914-C856706CBFE0

P3181

P356

P1433

Neuropsychopharmacology

P1476

Proof-of-concept trial with th ...... tive symptoms in schizophrenia

@en

P2093

A Leslie Morrow

http://www.w3.org/2001/XMLSchema#string

Adam J Savitz

http://www.w3.org/2001/XMLSchema#string

Christine E Marx

http://www.w3.org/2001/XMLSchema#string

Daniel W Bradford

http://www.w3.org/2001/XMLSchema#string

Jason D Kilts

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Lieberman

http://www.w3.org/2001/XMLSchema#string

Jennifer C Naylor

http://www.w3.org/2001/XMLSchema#string

Jennifer L Strauss

http://www.w3.org/2001/XMLSchema#string

Lawrence Dunn

http://www.w3.org/2001/XMLSchema#string

Lawrence J Shampine

http://www.w3.org/2001/XMLSchema#string

P2860

Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial

Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder

Progesterone exerts neuroprotective effects after brain injury

Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease

Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars

D-serine added to clozapine for the treatment of schizophrenia

Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression

A rating scale for drug-induced akathisia

P2888

P304

1885-1903

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2402029

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NPP.2009.26

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24251617

http://www.w3.org/2001/XMLSchema#string

P6179

1003294335

http://www.w3.org/2001/XMLSchema#string

P698

19339966

http://www.w3.org/2001/XMLSchema#string

P921

P932

3427920

http://www.w3.org/2001/XMLSchema#string